

**From:** Maruna, Thomas  
**Sent:** Thursday, March 10, 2016 10:01 AM  
**To:** 'Denloye, Aderonke O'  
**Subject:** March 10. 2016 Information Request - BLA 125596.0 - Please Respond by March 24. 2016

**Importance:** High

Baxalta US Inc.  
Attention: Ms. Aderonke Denloye  
March 10, 2016  
Sent by email

Dear Ms. Denloye:

We are reviewing your September 14, 2015 biologics license application (BLA) to treat primary immune deficiency disorders associated with defects in humoral immunity for the following:

<b>STN</b>	<b>Name of Biological Products</b>
125596/0	Immune Globulin Subcutaneous (Human), 20% Solution

We have determined the following information is required to continue our review:

1. Please provide concentration-time data for total IgG following SC administration for pediatrics (0-<6 and 6 to 12 years of age). Please show the method for the estimation of PK parameters.

In order to compare the pediatric PK with adults, select the same time points as of aforementioned pediatric age groups from adults and estimate the PK parameters in adults. Method for the estimation of PK parameters should be similar for children and adults.

2. In a tabulated form, please provide each subject's age, body weight, gender, ethnicity, and dose.

Please submit your responses as an amendment to this file by March 24, 2016 referencing the date of this request.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

The action due date for these files is September 13, 2016.

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP), CPH

Lieutenant, U.S. Public Health Service  
Senior Regulatory Management Officer  
Food and Drug Administration  
Center for Biologics Evaluation and Research  
Office of Blood Research and Review  
10903 New Hampshire Ave.  
Silver Spring, MD 20993  
[thomas.maruna@fda.hhs.gov](mailto:thomas.maruna@fda.hhs.gov)  
O: (240) 402-8454  
[www.usphs.gov](http://www.usphs.gov)



"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.